Warren, Audrey L. http://orcid.org/0000-0002-1538-8648
Lankri, David http://orcid.org/0000-0002-1210-5673
Cunningham, Michael J.
Serrano, Inis C. http://orcid.org/0000-0002-3588-821X
Parise, Lyonna F. http://orcid.org/0000-0002-7527-8977
Kruegel, Andrew C.
Duggan, Priscilla http://orcid.org/0000-0002-9728-282X
Zilberg, Gregory
Capper, Michael J. http://orcid.org/0000-0003-0102-6993
Havel, Vaclav http://orcid.org/0000-0002-6911-4669
Russo, Scott J. http://orcid.org/0000-0002-6470-1805
Sames, Dalibor http://orcid.org/0000-0001-6911-2260
Wacker, Daniel http://orcid.org/0000-0003-4951-7230
Article History
Received: 14 February 2023
Accepted: 9 April 2024
First Online: 8 May 2024
Competing interests
: The authors declare the following competing financial interests: D.S. and A.C.K. are co-founders of Gilgamesh Pharmaceuticals and Kures. M. J. Cunningham is a co-founder of Gilgamesh Pharmaceuticals. A.L.W., D.L., I.C.S., L.F.P., S.J.R., D.S. and D.W. are inventors on a patent application related to the featured compound class. D.W. has consulted for Otsuka Pharmaceutical, Longboard Pharmaceuticals and Ocean Bio on the design of psychedelic-based therapeutics. None of the companies listed herein contributed to the funding or experimental design. All other authors declare no competing interests.